• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Clene Inc.

    11/14/24 3:32:55 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLNN alert in real time by email
    SC 13G/A 1 Clene13g123123t.txt CLNN 13GA THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Clene, Inc. (Name of Issuer) Common Stock, $0.0001 Par Value (Title of Class of Securities) 185634102 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) *The remainder of this cover page shall be filled out for a reporting person?s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 185634102 (1) Names of Reporting Persons. I.R.S. Identification Nos. of Above Persons (entities only): AWM Investment Company, Inc. (2) Check the Appropriate Box if a Member of a Group (See Instructions) (a)___ b)___ (3) SEC Use Only (4) Citizenship or Place of Organization: Delaware, United States Number of Shares Beneficially Owned by Each Reporting Person With (5) Sole Voting Power: 12,691,213** (6) Shared Voting Power: 0** (7) Sole Dispositive Power: 12,691,213** (8) Shared Dispositive Power: 0** (9) Aggregate Amount Beneficially Owned by Each Reporting Person: 12,691,213** (10) Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions): (11) Percent of Class Represented by Amount in Row (9): 9.2%** (12) Type of Reporting Person (See Instructions): IA **AWM Investment Company, Inc., a Delaware corporation (AWM), is the investment adviser to Special Situations Cayman Fund, L.P. (CAYMAN), Special Situations Fund III QP, L.P. (SSFQP) and Special Situations Life Sciences Fund, L.P. (SSLS). (CAYMAN, SSFQP, and SSLS will hereafter be referred to as the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 2,691,213 shares of Common Stock of the Issuer (the Shares) and 5,382,426 Warrants*** to purchase Shares of Common Stock held by SSFQP, 1,617,574 Warrants*** to purchase Shares of Common Stock held by CAYMAN and 3,000,000 Warrants*** to purchase Shares of Common Stock held by SSLS. See Items 2 and 4 of this Schedule for additional information. *** The Warrants described herein may only be exercised to the extent that the total number of Common Shares then beneficially owned does not exceed 10% of the outstanding shares. Item 1(a). Name Of Issuer: Clene, Inc. Item 1(b). Address of Issuer?s Principal Executive Offices: 6550 South Millrock Drive, Suite G50 Salt Lake City, Utah 84121 Item 2(a). Name of Person Filing: The person filing this report is AWM Investment Company, Inc., a Delaware corporation (AWM), which is the investment adviser to Special Situations Cayman Fund, L.P., a Cayman Islands Limited Partnership (CAYMAN), Special Situations Fund III QP, L.P., a Delaware limited partnership (SSFQP) and Special Situations Life Sciences Fund, L.P., a Delaware limited partnership (SSLS), (CAYMAN, SSFQP, SSPE and SSLS, will hereafter be referred to as the Funds). The principal business of each Fund is to invest in equity and equity-related securities and other securities of any kind or nature. David M. Greenhouse (Greenhouse) and Adam C. Stettner (Stettner) are members of: SSCayman, L.L.C., a Delaware limited liability company (SSCAY), the general partner of CAYMAN; MGP Advisers Limited Partnership, a Delaware limited partnership (MGP), the general partner of SSFQP and LS Advisers, L.L.C., a New York limited liability company (LS). Greenhouse and Stettner are also controlling principals of AWM. Item 2(b). Address of Principal Business Office or, if None, Residence: The principal business address for AWM is c/o Special Situations Funds, 527 Madison Avenue, Suite 2600, New York, NY 10022. Item 2(c). Citizenship: AWM is a Delaware Corporation. Item 2(d). Title of Class of Securities: Common Stock, $0.0001 Par Value Item 2(e). CUSIP No.: 185634102 Item 3. If This Statement Is Filed Pursuant to ??240.13d-1(b) or 240.13d-2(b) or (c), check whether the Person Filing is a: Not Applicable. Item 4. Ownership (a) Amount Beneficially Owned: 12,691,213** (b) Percent of Class: 9.2%** (c) Number of Shares as to which the person has: (i) sole power to vote or to direct the vote: 12,691,213** (ii) shared power to vote or to direct the vote: 0** (iii) sole power to dispose or to direct the disposition of: 12,691,213** (iv) shared power to dispose or to direct the disposition of: 0** ______________________________________________________________________ ** AWM is the investment adviser to each of the Funds. As the investment adviser to the Funds, AWM holds sole voting and investment power over 2,691,213 shares of Common Stock of the Issuer (the Shares) and 5,382,426 Warrants*** to purchase Shares of Common Stock held by SSFQP, 1,617,574 Warrants*** to purchase Shares of Common Stock held by CAYMAN and 3,000,000 Warrants*** to purchase Shares of Common Stock held by SSLS. Greenhouse and Stettner are members of: SSCAY, the general partner of CAYMAN; MGP, the general partner of SSFQP; MG, the general partner of SSPE; and LS, the general partner of SSLS. Greenhouse and Stettner are also controlling principals of AWM. Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ___ Item 6. Ownership of More Than Five Percent on Behalf of Another Person Not Applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person Not Applicable. Item 8. Identification and Classification of Members of the Group Not Applicable. Item 9. Notice of Dissolution of Group Not Applicable. Item 10. Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 13, 2024 AWM INVESTMENT COMPANY, INC. By:/s/ Adam Stettner Name: Adam Stettner Title: Executive Vice President Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001) -1-
    Get the next $CLNN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLNN

    DatePrice TargetRatingAnalyst
    10/4/2022Outperform → Perform
    Oppenheimer
    7/18/2022$16.00Buy
    H.C. Wainwright
    5/2/2022$10.00Buy
    Canaccord Genuity
    9/28/2021$20.00Outperform
    Oppenheimer
    More analyst ratings

    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Presenting on Emerging Growth Conference 82 Day 2 on May 22; Register to live stream

      MIAMI, May 21, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1 – Presenting Today, May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go ba

      5/21/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream

      MIAMI, May 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 82nd Emerging Growth Conference on May 21 & 22, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: [email protected] For updates, follow us on Twitter Day 1May 21, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the

      5/20/25 7:00:00 AM ET
      $ASPI
      $ATCH
      $CIA
      $CLNN
      Major Chemicals
      Industrials
      Finance: Consumer Services
      Finance
    • Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

      Clene preparing for upcoming meeting in the second quarter with the U.S. Food and Drug Administration (FDA) to reach agreement on its statistical analysis plan (SAP) regarding analysis of neurofilament light chain (NfL) biomarker dataClene collecting NfL biomarker data from its large National Institute of Health (NIH)-sponsored Expanded Access Protocol (EAP), for evaluation in the third quarter to satisfy the FDA recommendation for additional NfL dataClene reported new data supporting the remyelination and neuronal repair associated with CNM-Au8® treatment in a late-breaking science session at the American Academy of Neurology (AAN) 2025 Annual MeetingClene released new data from a cross-reg

      5/7/25 8:00:00 AM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner General Resonance Llc sold $2,424 worth of shares (600 units at $4.04), decreasing direct ownership by 0.08% to 707,992 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      6/4/25 3:23:07 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner General Resonance Llc sold $2,473 worth of shares (600 units at $4.12), decreasing direct ownership by 0.08% to 708,592 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      6/2/25 2:39:49 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner General Resonance Llc sold $1,148 worth of shares (410 units at $2.80), decreasing direct ownership by 0.06% to 709,192 units (SEC Form 4)

      4 - Clene Inc. (0001822791) (Issuer)

      5/30/25 2:40:28 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLNN
    SEC Filings

    See more
    • Clene Inc. filed SEC Form 8-K: Other Events

      8-K - Clene Inc. (0001822791) (Filer)

      6/17/25 4:31:02 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Clene Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Clene Inc. (0001822791) (Filer)

      5/23/25 4:04:27 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SD filed by Clene Inc.

      SD - Clene Inc. (0001822791) (Filer)

      5/16/25 4:11:24 PM ET
      $CLNN
      Biotechnology: Pharmaceutical Preparations
      Health Care